Loading...
Loading...
NVCR| Name | Value |
|---|---|
| Revenues | 127.3M |
| Cost of Revenue | 32.1M |
| Gross Profit | 95.2M |
| Operating Expense | 153.5M |
| Operating I/L | -58.2M |
| Other Income/Expense | 10.0M |
| Interest Income | 10.0M |
| Pretax | -48.2M |
| Income Tax Expense | 1.3M |
| Net Income/Loss | -49.5M |
NovoCure Limited is an oncology company specializing in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers. Its flagship products include Optune for glioblastoma and Optune Lua for malignant pleural mesothelioma. The company generates revenue through the sale of these TTFields devices and ongoing or completed clinical trials investigating TTFields in various cancer types, including brain metastases, gastric cancer, liver cancer, and ovarian cancer.
